The company’s decision follows findings from the MOTheR and CONCORDIA studies presented at the 2026 European Renal Association meeting. These trials indicated that Expanded Hemodialysis (HDx) achieves clinical outcomes comparable to online hemodiafiltration without requiring the complex technical upgrades typically associated with that treatment. By utilizing membranes with larger, more uniform pores, these dialyzers effectively remove medium to large molecules linked to inflammation and cardiovascular complications.
U.S. Renal Care Expands Access to Advanced Dialysis Technology
U.S. Renal Care is broadening the availability of medium cut-off dialyzers across its national network, aiming to provide Expanded Hemodialysis to patients with end-stage kidney disease. This shift follows recent clinical data suggesting that the therapy improves middle-molecule clearance while maintaining the convenience of standard dialysis infrastructure.
Dr. Mary Dittrich, Chief Medical Officer at U.S. Renal Care, noted that the accumulation of clinical evidence supports the transition for eligible patients. Beyond improved solute clearance, research suggests patients may experience better sleep, faster recovery times, and reduced symptom burdens such as restless legs. Economic analysis also points toward potential reductions in hospitalizations and total care costs compared to standard high-flux hemodialysis. The technology is currently being deployed in selected centers, with plans for a wider rollout to support the provider's 37,000 patients across 32 states.
Comments (0)
No comments yet. Be the first!